Le Professeur Lebwaze a été invité par l’Alliance Mondiale Contre le Cancer (AMCC) pour parler de son expérience sur le diagnostic des hémopathies malignes par l’immunohistochimie. Il a eu à colliger environ 132 patients sur 3 ans comme on pourrez le lire à travers l’abstract ci-dessous.
IMMUNOPHENOTYPE OF AGGRESSIVE B-LYMPHOMAS IN DEMOCRATIC REPUBLIC OF CONGO (DRC)
BMLEBWAZEa, FL BOKAMBANDJAa, SL KANZAa, RMKALENGAYIa, M RAPHAËLb
(a) University of Kinshasa, Faculty of Medicine, Department of Pathology, Kinshasa, DRC
(b) Faculty of Medicine, University Paris-Sud 11, Bicêtre, France
CORRESPONDENCE: Bienvenu Massamba LEBWAZE: bienvenulebwaze@gmail.com
Introduction
Aggressive B-Lymphomas are the most frequent cancers in developping countries. Their high frequency correlates with HIV incidence. Immunophenotype of this group of lymphoma is discussed in this study.
Material and Methods
We reviewed 132 embedded paraffin blocks of aggressive lymphomas from6 pathology laboratories inDRC among which 18 patients were HIV positive while 114 were either HIV unknown or negative. All blocks were processed according to standard hematoxyline-eosine, immunohistochemical .
Results
Our findings show: 48 BL including 5 HIV positive (10,4%), 66 DLBCL including 9 HIV positive (13,6%) and 18 intermediate forms including 4 HIV positive (22,2%). Most of them were CD20+ (116/132: 87,8%) but all BL were CD20+and CD10+, BL HIV+ express LMP1 in 2 cases/5 (40%).For DLBCL: 80% had extranodal presentation, 65% GCB subtype vs 35 ABCsubtype and CD5 was positive in 23,3%. Intermediate forms had an immunoprofile between both BL and DLBCL.
Conclusion:
our findings show that aggressive lymphomas present particularities of immunophenotype in RDC.
Key words: aggressive lymphoma, immunophenotype, DRC.